Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EO2040
- Development stage
- Discontinued
- Lead developer
- Enterome
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
EO2040 is an innovative, off-the-shelf peptide-based immunotherapy developed by Enterome. It consists of two synthetic OncoMimics peptides, which are non-self, microbial-derived peptides designed to mimic CD8 HLA-A2 epitopes corresponding to the tumor-associated antigens Forkhead box protein M1 (FOXM1) and Baculoviral IAP repeat-containing protein 5 (survivin). Additionally, EO2040 includes universal cancer peptide 2 (UCP2), a helper peptide representing a CD4+ epitope. The therapy aims to stimulate both cytotoxic and helper T cell responses against these tumor antigens through molecular mimicry. EO2040 is being evaluated as a therapeutic cancer vaccine in patients with circulating tumor DNA-defined minimal residual disease relapse of advanced colorectal cancer. It is currently in Phase 2 clinical trials as monotherapy and in combination with the checkpoint inhibitor nivolumab[1][3][4][5].
- Other names
- EO2040EO-2040EO 2040
02
Targets
Forkhead box M1-derived CD8+ T-cell epitopeHLA-A*02 (Human leukocyte antigen A*02 complexed peptide)BIRC5 (Survivin)FOXM1 (Forkhead box protein M1)
Beyond the preview
Go deeper on EO2040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EO2040.